Xenon projects top line X-TOLE2 data in early 2026 as enrollment surpasses target, expanding late-stage pipeline
                    
                        Earnings Call Insights: Xenon Pharmaceuticals Inc. (XENE) Q3 2025 Management View Ian Mortimer, President and CEO, highlighted three critical priorities: completion of the Phase III X-TOLE2 study of azetukalner for focal onset seizures with top line data...                    
                    
                        
                        
                            Seeking Alpha